An Open Label Study to Determine the Absolute Oral Bioavailability of Quizartinib Using a Radiolabeled Microtracer in Healthy Subjects
Latest Information Update: 20 Feb 2024
At a glance
- Drugs Quizartinib (Primary) ; Quizartinib
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Pharmacokinetics
- Sponsors Daiichi Sankyo Inc
- 24 Mar 2023 Results assessing the pharmacokinetics (absolute oral bioavailability) of quizartinib using an IV microdose of 14C-quizartinib in healthy subjects, presented at the 124th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 24 Sep 2021 Status changed from recruiting to completed.
- 04 May 2021 Status changed from not yet recruiting to recruiting.